Scientists test 'Living Drug' to reboot immune system in severe lupus
NCT ID NCT06935474
Summary
This early-stage study is testing a new personalized cell therapy called C-CAR168 for people with severe lupus kidney disease that hasn't improved with standard treatments. Doctors will collect a patient's own immune cells, genetically modify them to target specific markers on harmful immune cells, and infuse them back. The main goals are to find a safe dose and see if this one-time treatment can help control the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUPUS NEPHRITIS (LN) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
AbelZeta, Inc.
Rockville, Maryland, 20850, United States
Conditions
Explore the condition pages connected to this study.